

FDA CLEARS ABBOTT'S ALINITY H-SERIES LAB INSTRUMENTS, ENABLING ADVANCED TESTING OF PATIENTS' COMPLETE BLOOD COUNTS

- With the addition of the Alinity® h-series, Abbott now has one of the broadest diagnostic offerings for laboratories
- The Alinity h-series hematology system will seamlessly integrate into existing Alinity lab systems across the country
- The addition will expand laboratories' capabilities, allowing hospitals to more easily measure complete blood counts, one of the most ordered healthcare tests for patients

ABBOTT PARK, Ill., Aug. 7, 2023 — Abbott has received U.S. Food and Drug Administration clearance for its advanced Alinity® h-series hematology system, paving the way for laboratories throughout the country to run complete blood counts (CBC) as a part of Abbott's [Alinity family](#) of diagnostic products.

Complete blood counts are one of the most ordered tests in the healthcare system and are common in routine checkups because they can help screen for a variety of disorders including infections, anemia, diseases of the immune system, and blood cancers.

The Alinity h-series includes Alinity hq, an automated hematology analyzer, and Alinity hs, an integrated slide maker and stainer. A key differentiator for Alinity hq is that it leverages the advanced MAPSS™ technology, which uses light scattering to distinguish cellular features and better identify various blood cells.

With the Alinity h-series, Abbott now offers one of the broadest laboratory diagnostic systems, providing a wide array of tests doctors can use to quickly and effectively care for their patients. Laboratories and hospitals across the U.S. will be able to seamlessly integrate the Alinity h-series hematology system into their existing core lab operations, allowing lab staff to easily adopt with minimal effort and training. This is especially important in labs where time, resources and staff are stretched thin.

"U.S. healthcare systems have experienced significant resource constraints and rapidly shifting dynamics post-pandemic," said Louis Morrone, executive vice president for Abbott's core diagnostics business. "The Alinity h-series system, as with the entire suite of Alinity products, was developed to transform the way laboratories run tests so they can focus on their most important mission: the delivery of patient care."

The Alinity family of systems in the U.S. now includes the Alinity h-series (hematology), Alinity ci (clinical chemistry and immunoassay), Alinity m, (molecular), Alinity s (transfusion) and the point-of-care i-STAT Alinity.

The Alinity h-series system offers several advantages for laboratories:

- Processes up to 119 CBC results per hour, among the fastest on the market
- Requires less floor space, which is critical for labs to maximize resources and operations
- Loads samples from the front and from a laboratory automation system
- Ensures urgent samples receive priority without compromising capacity or workflow
- Offers hands-off maintenance so labs can schedule automated daily and weekly cleanings
- Integrates the slide maker with the analyzer to reduce manual intervention
- Provides customizable reports and rules for systems
- Centralizes results and control functions at a single point

About Alinity

Abbott's Alinity family of harmonized solutions is unprecedented in the diagnostics industry, working together to address the challenges of using multiple diagnostic platforms and simplifying diagnostic testing. Alinity systems are designed to be more efficient – running more tests in less space, generating test results faster and minimizing human errors – while continuing to provide quality results. The availability of the Alinity systems and tests varies by geography. More information is available at [alinity.com](https://www.alinity.com).

About Abbott

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 115,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott/, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews.

For further information: Abbott Media: Patrick O'Connell, 847-282-2649; Abbott Investor Relations: Ryan Aliff, 224-667-2299
